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ORIGINAL ARTICLE

Tuberculous and Cryptococcal Meningitis in a Setting with
High TB and Low HIV Prevalence
Afrasyab Khan1, Bushra Jamil2, Rahmat Ali3 and Sana Sultan4

ABSTRACT
Objective: To compare the differences in presentation and outcome of patients with tuberculous meningitis (TBM) and
cryptococcal meningitis (CCM).
Study Design: Case series.
Place and Duration of Study: The Aga Khan University Hospital, Karachi, from December 1995 to December 2005.
Methodology: Patients with a confirmed diagnosis of TBM or CCM were included in this study. The signs and symptoms,
laboratory findings and other variables of patients were entered and analyzed by Statistical Package for Social Sciences
(SPSS) Software version 14.
Results: We compared 16 patients of TBM with 11 of CCM. None of the patients with TBM were Human Immunodeficiency
Virus (HIV) positive while 4 patients with CCM had HIV. The common initial signs and symptoms in patients with TBM were
fever, altered mental status and headache; and in patients with CCM were fever, headache and cough. The mean CSF
glucose level decreased according to the Medical Research Council (MRC) stage in TBM. The mean CSF RBCs, WBCs,
glucose and protein in TBM were 2010/mm3, 228/mm3, 52.32mg/dL and 289.48mg/dl respectively and in CCM were
178.54/mm3, 529.54/mm3, 32.63mg/dL and 432.18mg//dL respectively.
Conclusion: TBM and CCM should be suspected in all cases that present with symptoms of chronic meningitis. Patients
with TBM are more likely to have altered mental status and higher CSF RBCs; those with CCM are more likely to have
headache, cough and higher CSF WBCs.
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INTRODUCTION
The classification of meningitis can be based on its
underlying cause or time course of the illness. It can be
classified as acute or chronic based on the time course.
The two most common types of chronic meningitis are
tuberculous meningitis (TBM) and cryptococcal
meningitis (CCM).1,2 Tuberculous meningitis is a serious
health problem due to high prevalence of pulmonary
tuberculosis in most developing countries and the
increasing prevalence of HIV infection worldwide.3,4 In
Africa, tuberculous meningitis is the main neurological
complication among HIV-infected patients.5 Also HIV
infection is commonly complicated by infection with
Mycobacterium tuberculosis in areas of high prevalence
of tuberculosis. While in areas where the incidence rate
is lower such as North America and Western Europe,
extrapulmonary infection is seen primarily in adults with
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reactivation disease and the dominant form of CNS
infection is meningitis. TBM with HIV presents usually
with both pulmonary and extra-pulmonary involvement.6,7 Mycobacterium tuberculosis infects the central
nervous system in three main forms: cerebral abscess
and tuberculoma, meningitis and myelopathy.8-13 The
classic cerebrospinal fluid (CSF) profile in TBM is
lymphocytosis, high protein and low glucose.
Cryptococcal meningitis occurs in 5 to 8 percent of
patients with the acquired immunodeficiency syndrome
(AIDS),14,15 nevertheless, it is the most common lifethreatening opportunistic fungal infection in patients
infected with HIV type-1.14 Cryptococcal meningitis can
also be called meningoencephalitis because the brain
parenchyma is almost always involved in this disease.
The incidence of CCM has increased in recent years
and apart from HIV infection, it is also seen in
association with extensive antibiotic use and use of
immunosuppressive agents.16 CCM usually has the
same clinical features and CSF findings as TBM.1,2
Visual impairment, marked elevation of CSF pressure,
papilledema and normal CSF protein usually occur in
CCM, while marked elevation of CSF protein content
(> 2 g/L) usually occurs in TBM.17 However, CSF protein
content may be variable and in one study of HIV-infected
patients, 43% of patients with TBM had normal CSF
protein concentrations.12
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Thus, the clinical presentation and CSF findings of TBM
and CCM can be similar and it is usually difficult to
decide one-way or the other until a confirmed laboratory
result detecting the presence of the organism is
received. Additionally, the incidence of both TBM and
CCM is higher in immunocompromised patients.18
Usually, these patients undergo complex diagnostic
investigations including serological assays, multiple
imaging and repeated lumbar punctures. To avoid
unnecessary investigations, the type of laboratory
testing should be based upon a good history and clinical
findings in the patient and the subsequent probability
that a specific disease is present.
The specific objective was to find the differences in
predisposing factors, presentation, laboratory findings
and outcome of patients with TBM and CCM to aid in
early diagnosis.

METHODOLOGY
A comparison of the case series of TBM and CCM was
done by a review of patient records and data of patients
with confirmed diagnosis of TBM and CCM during a
period of 10 years (December 1995 through December
2005) at the Aga Khan University Hospital, Karachi. The
selection criteria was a confirmed diagnosis of TBM or
CCM. The diagnosis of TBM was confirmed by either a
positive CSF culture of M. tuberculosis or by signs,
symptoms along with suggestive results of investigations and good response to anti-tuberculosis
medications. The investigations included biochemical
and cytological profile of CSF compatible with TBM
and/or suggestive findings on Computed Tomography
(CT) or Magnetic Resonance Imaging (MRI). The
diagnosis of CCM was confirmed by either a positive
CSF smear, cryptococcal antigen test of CSF or CSF
culture.
Those patients who left the hospital against medical
advice after diagnosis and whose full workup was not
completed were excluded from the study. Informed
consent was also taken allowing the use of medical
records for the purpose of research at the time of
admission, while keeping the records completely
confidential at the same time.
The signs and symptoms, laboratory findings, past
medical history, significant concurrent illnesses, factors
leading to compromised host status and BCG
vaccination status were studied. Data on demographics
and complications of illness was also collected as well
as the outcome of initial treatment in TBM and CCM.
Data was entered in Statistical Package for Social
Sciences (SPSS) Software version 14. The mean
standard deviations and percentages of relevant
variables were calculated. Tests of significance were not
performed due to the small sample size.
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RESULTS
The total number of TBM cases were 18. Of those, 2
patients left the hospital against medical advice after
diagnosis and data could not be completed from their
records, so these patients were excluded from the study.
Therefore, a total of 16 cases of tuberculous meningitis
were included in this study. Of those, only one patient
had positive CSF cultures for M. tuberculosis. The CSF
cultures were negative for any growth in the rest and the
diagnosis was on clinical grounds along with suggestive
CSF biochemical and cytological profile and findings
compatible with TB on CT or MRI. Of the 16 cases, 12
(75%) were male and 4 (25%) female with a mean age
of 47.56 + 11.73 years. Three had a previous history of
pulmonary TB, one had a previous history of TB
meningitis, and two had a previous history of
hydrocephalus and a ventriculo-peritoneal shunt. None
of the patients were HIV positive.
The main initial signs/symptoms of the patients at
presentation were fever (81.3%), altered mental status
(68.8%), headache (62.5%), vomiting (56.3%), neck
stiffness (56.3%), seizures (25%) and weight loss
(18.8%). Two patients had hemiperesis and 3 had back
pain, 2 had photophobia and 3 had cranial nerve
abnormalities. The cranial nerves involved were
abducens, facial and hypoglossal, one in each of the
cases (Table I).
The mean white cell count was of CSF 228/mm3
+ 291.59/mm3. Four cases showed a preponderance of
neutrophils in CSF while the remaining 11 cases of TBM
showed increase in lymphocytes. Mean CSF RBCs
were 2010.75/mm3 + 4904.93/mm3. The mean CSF
glucose level was 52.33 + 32.33 mg/dL. In 9 cases, the
CSF glucose level was less than 50mg/dL with mean of
34.44 + 9.74 mg/dL. In 7 cases, the CSF glucose level
was greater than 50 mg/dL with a mean 75.57 + 32.54
mg/dL. The mean CSF protein was 289.48 + 212.69
mg/dL. Nine patients had a CSF protein of less than 250
mg/dL with a mean 177.11 + 41.13 mg/dL. Seven
patients had a CSF protein of greater than 250 mg/dL
with a mean 433.95 + 259.89 mg/dL. The mean
hemoglobin level was 13.41 + 1.64 g/dL. Nine patients
had hemoglobin levels less than 13.7 g/dL with a mean
12.28 + 1.24 g/dL. The mean blood WBC count was
9
12.31 + 5.18 x 10 /L. Eleven patients had leukocytosis
i-e a WBC count greater than the normal value of 10 x
9
9
10 /L (mean = 15.03 + 4.07 x 10 /L, Table II).
Of the 16 patients with TBM, 3 were determined to be in
clinical stage 1 of the Medical Research Council (MRC)
criteria (Table III), 11 in stage 2 and 2 in stage 3. The
mean CSF glucose level decreased according to the
stage. Mean CSF glucose was 65.66 m/dL in stage 1,
51.45 mg/dL in stage 2 and 38.00 mg/dL in stage 3.
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Table I: Presenting symptoms and signs in patients with TBM and
CCM.
Sign and symptoms

Fever
Headache
Vomiting
Neck Stiffness
Cough
Backache
Weight loss
Seizures
Photophobia
Arthralgia
Hemiperesis
Altered mental status
Cranial nerve involvement

TB Meningitis
Cryptococcal Meningitis
n=16
n=11
Number of patients (%) Number of patients (%)
13 (81.3)
10 (90.9)
10 (62.5)
8 (72.7)
9 (56.3)
2 (18.2)
9 (56.3)
4 (36.4)
1 (6.3)
6 (54.5)
3 (18.8)
2 (18.2)
3 (18.8)
3 (27.3)
4 (25)
1 (9.1)
2 (12.5)
0 (0)
1 (6.3)
1 (9.1)
2 (12.5)
3 (27.3)
11 (68.8)
4 (36.4)
2 (12.5)
2 (18.2)
Figure 1: Comparison of lab findings in patients with TBM and CCM.

Table II: Lab findings in patients with TBM and CCM.
Lab findings

TB Meningitis
Cryptococcal Meningitis
Range
Mean +
Range
Mean +
standard deviation
standard deviation
Hemoglobin (g/dl)
13.41 + 1.64
5.20
10.75 + 2.60
8.30
Platelets (x109/L)
285.5 + 145.06
486.00
233.27 + 98.18
270.00
Blood WBCs (x109/L)
12.31 + 5.18
20.50
8.7 + 3.8
14.30
CSF WBCs (/mm3)
228 + 291.59
1038.00 529.54 + 756.61 2006.00
CSF RBCs (/mm3)
2010.75 + 4904.93 17896.00 178.54 + 300.92 981.00
CSF PMN (%)
35.20 + 29.44
88.00
40 + 39.15
90.00
CSF Lymphocytes (%)
62.13 + 30.72
88.00
60 + 39.15
90.00
CSF Glucose (mg/dl)
52.43 + 30.3
126.00
32.63 + 26.30
75.00
CSF Protein (mg/dl)
289.48 + 212.69 1009.00 432.18 + 761.05 2657.00
WBCs = White blood cells; RBCs = Red Blood Cells; CSF = Cerebrospinal Fluid.

Table III: Medical Research Council (MRC) criteria for meningitis.22
Stage 1 (early)
Stage 3 (advanced)
Stage 2 (medium)

Patients with no or minimum signs and symptoms of
meningitis and diagnosis mainly based on CSF findings.
Patients who are in deep stupor or comatose or have
paresis.
Patients whose condition is in between the above two
groups.

Apart from symptomatic treatment, Isoniazid, rifampin,
pyrazinamide and ethambutol along with corticosteroids
were prescribed in all 16 cases and mannitol in 3 cases
of TBM. All patients showed marked improvement and
were discharged on anti-tuberculosis regimen.
The total number of CCM cases were 12, one patient
was excluded from the study because the patient left the
hospital against medical advice after diagnosis for
treatment elsewhere and complete data could not be
obtained. Thus a total of 11 cases of cryptococcal
meningitis were diagnosed. Nine patients were male
and 2 female. The mean age was 50.63 + 11.84 years.
CSF culture was performed in 7 patients and was
positive in all cases. India ink test was positive in 5
cases. Four out of 11 patients were HIV positive. Of
those 4, 2 were identified as HIV positive for the first
time after a diagnosis of cryptococcal meningitis was
made. All HIV positive patients were male.
The main signs and symptoms at presentation were
fever (90.9%), headache (72.7%), cough (54.5%) and
neck stiffness (36.4%). Others included altered mental

status (36.4%), hemiparesis (27.3%). Cerebral
infarction was identified in 3 patients on CT. Two
patients had cranial nerve involvement; in one facial and
vagus and in the other facial abducens. Three patients
had presented at other hospitals initially where antituberculosis therapy was started but were referred
within 5 days, as there was no improvement.
The mean CSF white cell count was 529.54
+ 756.61/mm3. Seven cases showed an increase in
lymphocytes in CSF while 4 showed a preponderance of
neutrophils (Figure 1). Mean CSF RBCs was 178.54 +
300.92/mm3. Two patients had normal CSF glucose
levels; the rest had decreased CSF glucose. The mean
CSF glucose level was 32.63 + 26.30 mg/dL. Only one
patient had normal CSF protein level. The mean CSF
protein level was 432.18 + 761.05 mg/dL. Eight patients
had CSF protein levels less than 250 mg/dL with a mean
of 151.75 + 65.53 mg/dL. The mean hemoglobin level
was 10.75 + 2.60 g/dL. Ten patients had hemoglobin
levels less than 13.7 g/dL. The mean blood white cell
9
count was 8.7 + 3.88 x 10 /L (Table II).
Of the 11 patients with CCM, 4 were in clinical stage 1,
4 in stage 2 and 3 in stage 3. The mean CSF glucose
levels in stage 1, 2 and 3 were 36.75 mg/dL, 11.25
mg/dL and 55.66 mg/dL respectively. The mean CSF
protein levels in stage 1, 2 and 3 were 747.25 mg/dL,
296.5 mg/dL and 193 mg/dL respectively.
All patients were treated with a combination of
amphotericin B and fluconazole. Except 3 patients who
were initially started on anti-fungal treatment, the rest
were initially started on anti-tuberculosis therapy on
presentation. After positive CSF reports and/or antigen
testing, antifungal therapy of amphotericin B and
fluconazole was started. All patients were given
corticosteroids and 2 patients were also given mannitol.
Of the 11 patients, 2 expired during hospital stay, while
9 were discharged.
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CONCLUSION

DISCUSSION
None of the patients with TBM were infected with HIV. A
study in Chile found 30% of patients with TBM infected
with HIV out of 53 cases.19 Four out of 11 patients with
cryptococcal meningitis were HIV positive. The
remaining 7 patients had no apparent cause for
immunosuppression. They had no past medical history
of transplant, Hodgkin’s disease, sarcoidosis or any
condition leading to immunity compromise except in one
case in which the patient was diabetic.
There were several differences of signs and symptoms
between the two groups (Table I). Nine patients (56.3%)
with TBM had vomiting as opposed to 2 (18.2%) patients
with CCM. Only 1 patient (6.3%) with TBM had cough,
while 6 patients (54.5%) with CCM complained of
cough. Altered mental status was more common in
patients with TBM. Eleven patients (68.8%) with TBM
had altered mental status as opposed to 4 patients
(36.4%) with CCM. In the study by Enburg et al. 66% of
patients with TBM had altered mental status.19 It is
important to note that neck stiffness was not reported in
44% patients with TBM and in 64% patients with CCM.
Four patients (25%) with TBM experienced seizures
while only 1 (9.1%) with CCM had seizures. It is
essential that clinicians are aware that the classic signs
and symptoms of meningitis are not present in many
patients with the disease. Thus, the index of suspicion
must be very high for this disease and CSF analysis
done early. Apart from the presenting signs and
symptoms, the latest rapid diagnostic tests can be used
wherever available, like the ex vivo Mycobacterium
tuberculosis-specific enzyme-linked immunospot assay
(ELISPOT).20 This assay is able to detect an immune
response to M. tuberculosis in the CSF of patients and
can reliably confirm a diagnosis of tuberculous
meningitis. Similarly, enzyme immunoassay can be
used for a rapid diagnosis of CCM.21
Except one HIV positive case of CCM, in whom the CSF
WBC count was within normal range, there was an
increase in CSF WBCs in all cases of CCM and TBM.
The mean CSF protein in TBM was 52.43 mg/dL as
opposed to 32.63 mg/dL in CCM. The mean CSF RBCs
in TBM was 2010/mm3, while in CCM, it was
178.54/mm3. The mean CSF glucose in TBM was
52.43 mg/dL while in CCM, it was 32.63 mg/dL. Thus,
the mean concentration of proteins, RBCs, and glucose
in the CSF of patients with TBM was higher than those
with CCM. It should be noted that a number of patients
with TBM have normal CSF glucose levels. Two patients
with CCM expired during hospital stay. One of them was
HIV positive and the other was diabetic. The rest
responded well to initial therapy, completed the course
of amphotericin B and were alive till their last follow-up
in the clinic.
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TBM and CCM should be suspected in all cases that
present with symptoms of chronic meningitis. A high
index of suspicion is valuable in this setting, which has
a high prevalence of tuberculosis. Also, the low
prevalence of HIV in Pakistan should not exclude the
differential diagnosis of CCM as most of the cases in this
study with CCM were not HIV positive. Patients with
TBM are more likely to have altered mental status and
higher CSF RBCs; those with CCM are more likely to
have headache, cough and higher CSF WBCs. The
possibility of CCM should be kept in mind and an India
ink staining of CSF done wherever available.
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